Dutch reimbursement authority suggests Roche's off-label Avastin for wet AMD instead of Novartis' Lucentis
This article was originally published in Scrip
Executive Summary
The Dutch government is currently mulling whether or not to follow a recommendation from the CVZ, which gives advice on which treatments health insurers should fund, to "conditionally delist" Novartis' Lucentis (ranibizumab) as a second-line treatment for wet AMD, behind off-label Avastin (Roche's bevacizumab).